$1.84−0.12 (−6.12%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Pacific Biosciences of California (PACB) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~5.2%/yr (FY21→FY25), net margin −341.5%. Worth your attention in FY25: Share count (+46.9%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲3.9%
160.0
FY21→FY25CAGR +5.2%/yr
Net income ($M)▼76.3%
−546.4
one-off year: see footnoteCAGR —
Free cash flow ($M)▲46.3%
−113.9
FY21→FY25CAGR —
Diluted EPS▼14.5%
−1.82
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+46.9%
204.1mn → 300.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$2.7M
−56.1% YoY in FY25 · 1.7% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-341¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 45.1% → 28.6%. Net margin -341.5% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 161,394.0 | 160,005.0 | 154,014.0 | 200,521.0 | 128,304.0 | 130,513.0 | ▲3.9% | +5.2% |
Cost of revenue | 105,879.0 | 114,225.0 | 116,732.0 | 147,741.0 | 79,269.0 | 71,653.0 | ▼2.1% | +12.4% |
Gross profit | 55,515.0 | 45,780.0 | 37,282.0 | 52,780.0 | 49,035.0 | 58,860.0 | ▲22.8% | −6.1% |
Research & development | 85,732.0 | 97,307.0 | 134,922.0 | 187,170.0 | 193,000.0 | 112,899.0 | ▼27.9% | −3.6% |
Selling, general & admin | 128,013.0 | 141,493.0 | 175,017.0 | 169,818.0 | 160,854.0 | 124,124.0 | ▼19.2% | +3.3% |
Total operating expenses | 186,681.0 | 599,641.0 | 511,595.0 | 387,247.0 | 356,231.0 | 269,295.0 | ▲17.2% | +22.2% |
Operating incomefeeds ROC rank | −131,166.0 | −553,861.0 | −474,313.0 | −334,467.0 | −307,196.0 | −210,435.0 | ▼16.8% | — |
Other income, net | 646.0 | 7,803.0 | 164,778.0 | 16,308.0 | −7,052.0 | −64,437.0 | — | — |
Pretax income | −130,520.0 | −546,058.0 | −309,535.0 | −318,159.0 | −314,248.0 | −274,872.0 | ▼76.4% | — |
Income tax | 713.0 | 318.0 | 316.0 | −11,424.0 | 0.0 | −93,649.0 | ▲0.6% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −131,233.0 | −546,376.0 | −309,851.0 | −306,735.0 | −314,248.0 | −181,223.0 | ▼76.3% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.40 | −1.82 | −1.59 | −1.21 | −1.40 | −0.89 | ▼14.5% | — |
Diluted shares (mn) | 311.25 | 299.96 | 288.37 | 253.63 | 224.55 | 204.14 | ▲4.0% | +10.1% |
| Margins | ||||||||
Gross margin12th pct in Healthcare | 34.4% | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% | ▲4.4pp | −16.5pp |
Operating margin | −81.3% | −346.2% | −308.0% | −166.8% | −239.4% | −161.2% | ▼38.2pp | −184.9pp |
Net margin14th pct in Healthcare | −81.3% | −341.5% | −201.2% | −153.0% | −244.9% | −138.9% | ▼140.3pp | −202.6pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 34% vs a 0% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Pacific Biosciences of California's revenue last fiscal year?
Pacific Biosciences of California reported revenue of $160.0M in fiscal 2025, up 3.9% from fiscal 2024.
What was Pacific Biosciences of California's net income?
Pacific Biosciences of California reported net income of −$546.4M in fiscal 2025, a net margin of −341.5%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

